Physician profile
Barbara Cencora
NPI 1740248160
$2,737.55
in general payments reported to CMS, 2019-2025
20 companies · $652 in 2025
The $652 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $78.21 · 2021: $270 · 2022: $497 · 2023: $374 · 2024: $573 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,559 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,558.57 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $638.18 | 2019-2025 | Creon, Rinvoq |
| Janssen Biotech, INC. | $595.64 | 2021-2025 | Stelara, Tremfya, Simponi |
| Madrigal Pharmaceuticals | $255.98 | 2025 | Rezdiffra |
| Pfizer INC. | $213.45 | 2019-2025 | |
| Genzyme Corporation | $210.38 | 2022-2025 | |
| Celgene Corporation | $170.96 | 2022-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $137.62 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.23 | 2019-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $83.91 | 2022-2025 | Ibsrela |
| Olympus America INC. | $76.39 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $43.12 | 2025 | Voquezna |
| Daiichi Sankyo INC. | $34.74 | 2022-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $27.74 | 2019-2021 | |
| Braintree Laboratories, INC. | $27.68 | 2021-2025 | Sutab, Suflave |
| Gilead Sciences, INC. | $25.61 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $18.22 | 2025 | Iqirvo |
| Qol Medical, LLC | $17.60 | 2023 | Sucraid |
| Alexion Pharmaceuticals, INC. | $14.11 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.72 | 2025 | Dupixent |
| Medtronic, INC. | $13.27 | 2023 | Gi Genius |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Cencora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.